Tesamorelin 10mg

Research applications

• Full-length GHRH(1-44) receptor pharmacology research
• Growth hormone and IGF-1 axis regulation studies
• Comparative structure-activity research against truncated GHRH analogues
• Enzymatic degradation resistance research (hexenoyl modification)

What the literature reports on tesamorelin

Tesamorelin retains the full 44-residue sequence of native human GHRH, distinguishing it from truncated GHRH(1-29) analogues such as CJC-1295. The N-terminal hexenoyl modification is documented in the medicinal chemistry literature as conferring resistance to N-terminal proteolytic cleavage, extending the peptide's functional half-life without altering its core receptor-binding sequence.

GHRH receptor pharmacology

Because tesamorelin preserves the complete native GHRH sequence, receptor-binding studies have used it as a reference compound for characterising GHRH receptor pharmacology, reporting binding affinity and activation kinetics closely comparable to native GHRH itself, in contrast to the modified binding profiles reported for truncated analogues.

Growth hormone axis research

Clinical and preclinical research has examined tesamorelin's effects on the growth hormone and IGF-1 axis, with studies reporting sustained increases in IGF-1 levels following administration. This research has been particularly documented in the context of visceral adipose tissue physiology, an area where tesamorelin has an established regulatory history outside the research-reagent context covered by this catalogue.

Comparative GHRH-analogue research

Researchers studying structure-activity relationships across the GHRH analogue class frequently compare tesamorelin's full-length sequence against truncated variants such as CJC-1295, using the comparison to isolate which structural elements of native GHRH are required for receptor activation versus pharmacokinetic stability.

Visceral adipose tissue research

A distinctive strand of the tesamorelin literature examines its effects on visceral adipose tissue, an area of research that has generated a substantial regulatory and clinical evidence base outside the scope of research-grade material. Preclinical mechanistic work in this area has focused on how sustained GHRH receptor engagement and downstream IGF-1 signalling relate to adipocyte lipid handling in visceral fat depots specifically, as distinct from subcutaneous adipose tissue.

Enzymatic stability research

Analytical studies have characterised the specific contribution of the N-terminal hexenoyl modification to tesamorelin's resistance against N-terminal proteolysis, research that has informed the broader medicinal chemistry literature on acylation strategies for extending regulatory peptide half-life.

Laboratory handling

Tesamorelin should be stored as lyophilised powder at -20°C, protected from light and moisture, until reconstitution. As a larger 44-residue peptide, careful reconstitution technique, introducing diluent slowly along the vial wall and mixing gently, helps preserve structural integrity.

• Lyophilised powder: store at -20°C, protected from light, until reconstitution.
• Reconstitution: introduce diluent slowly along the vial wall; mix gently, do not shake.
• Post-reconstitution: 2-8°C for short-term laboratory use; avoid repeated freeze-thaw cycles.
• Each batch ships with a certificate of analysis confirming ≥99% purity by HPLC and identity by mass spectrometry.

See the peptide reconstitution and storage guide for a full protocol reference. This product is intended for laboratory research use only.